Full Press Release Details
Dr. DeCorte has served as our VP of Chemistry since April 2025. Prior to joining Immuneering, he served as VP of Business Development for Symeres, a transatlantic chemistry and drug discovery CRO with laboratories in Europe and the US. He is also the founder of Kodib, LLC, a consultancy firm that provides drug discovery and early development expertise to pharmaceutical and biotech organizations.
In 1993, Dr. DeCorte joined Johnson & Johnson. Over the course of his 20+ year career at J&J, he worked in the areas of HIV, mycology, oncology, pain, inflammation and metabolic disease and served as the scientific founder and head of chemistry of Entura, a natural products-based drug discovery venture of J&J.
Dr. DeCorte is a co-inventor of IMM-1-104, a compound that is currently being evaluated clinically by Immuneering for the treatment of advanced solid tumors including pancreatic cancer. He is also the co-inventor of INTELENCE, Johnson & Johnson’s first FDA-approved non-nucleoside reverse transcriptase inhibitor for the treatment of HIV.
Dr. DeCorte completed his undergraduate education in Bioengineering at the University of Gent, Belgium, followed by graduate and postdoctoral work in organic chemistry at the Université de Rennes, France, the University at Albany, NY, and Vanderbilt University in Nashville, TN.
Dr. DeCorte is the co-author of 29 peer-reviewed research papers and is listed as an inventor on more than 30 patents and patent applications.